Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Phase II Peprostat study 'a major milestone' says Ergomed's Andrew Mackie

Ergomed's (LON:ERGO) chief business officer Andrew Mackie and Ben Nichols, CEO of subsidiary Haemostatix spoke to Proactive's Andrew Scott about the start of recruiting for a phase IIb proof-of-concept study on Peprostat - which will be used to treat a surgical complication called intraoperative bleeding.

 
Meet Horizonte Minerals Plc, Tethyan Resources PLC, Green Dragon Gas Ltd. and Zenyatta Ventures at our event, London, 31 May 2017. Register here »
Why Invest In Ergomed Plc? Read More Here

Register here to be notified of future Ergomed Plc articles
View full ERGO profile View Profile

Ergomed Plc Timeline

Newswire
April 13 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use